Collegium Pharmaceutical, Inc. Share-based Payment Arrangement, Expense
Collegium Pharmaceutical, Inc. (COLL) reported Share-based Payment Arrangement, Expense of $32.40 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2025-02-27
- Collegium Pharmaceutical, Inc. share-based payment arrangement, expense for the quarter ending 2024-12-31 was $7.60M, a 8.48% increase year-over-year.
- Collegium Pharmaceutical, Inc. share-based payment arrangement, expense for the quarter ending 2024-09-30 was $7.32M, a 4.13% increase year-over-year.
- Collegium Pharmaceutical, Inc. share-based payment arrangement, expense for the quarter ending 2024-06-30 was $10.01M, a 41.57% increase year-over-year.
- Collegium Pharmaceutical, Inc. share-based payment arrangement, expense for the quarter ending 2024-03-31 was $7.47M, a 23.86% increase year-over-year.
- Collegium Pharmaceutical, Inc. share-based payment arrangement, expense for fiscal 2024 was $32.40M, a 19.40% increase from fiscal 2023.
- Collegium Pharmaceutical, Inc. share-based payment arrangement, expense for fiscal 2023 was $27.14M, a 18.63% increase from fiscal 2022.
- Collegium Pharmaceutical, Inc. share-based payment arrangement, expense for fiscal 2022 was $22.87M, a 5.69% decline from fiscal 2021.
- Collegium Pharmaceutical, Inc. share-based payment arrangement, expense for fiscal 2021 was $24.25M, a 10.70% increase from fiscal 2020.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $7.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $14.91M derived: sum of 2 quarters · filed 2025-02-27 | $24.93M derived: sum of 3 quarters · filed 2025-02-27 | $32.40M 10-K · filed 2025-02-27 | |
| 2024-09-30 | $7.32M 10-Q · filed 2024-11-07 | $17.33M derived: sum of 2 quarters · filed 2024-11-07 | $24.80M 10-Q · filed 2024-11-07 | $31.81M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2024-06-30 | $10.01M 10-Q · filed 2024-08-08 | $17.49M 10-Q · filed 2024-08-08 | $24.49M derived: sum of 3 quarters · filed 2025-02-27 | $31.52M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2024-03-31 | $7.47M 10-Q · filed 2024-05-09 | $14.48M derived: sum of 2 quarters · filed 2025-02-27 | $21.50M derived: sum of 3 quarters · filed 2025-02-27 | $28.58M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-12-31 | $7.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $14.03M derived: sum of 2 quarters · filed 2025-02-27 | $21.10M derived: sum of 3 quarters · filed 2025-02-27 | $27.14M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $7.03M 10-Q · filed 2024-11-07 | $14.10M derived: sum of 2 quarters · filed 2024-11-07 | $20.13M 10-Q · filed 2024-11-07 | $25.80M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $7.07M 10-Q · filed 2024-08-08 | $13.11M 10-Q · filed 2024-08-08 | $18.78M derived: sum of 3 quarters · filed 2025-02-27 | $24.15M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | $6.04M 10-Q · filed 2024-05-09 | $11.71M derived: sum of 2 quarters · filed 2025-02-27 | $17.08M derived: sum of 3 quarters · filed 2025-02-27 | $22.77M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $5.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $11.05M derived: sum of 2 quarters · filed 2025-02-27 | $16.74M derived: sum of 3 quarters · filed 2025-02-27 | $22.87M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $5.38M 10-Q · filed 2023-11-07 | $11.07M derived: sum of 2 quarters · filed 2023-11-07 | $17.20M 10-Q · filed 2023-11-07 | $22.12M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2022-06-30 | $5.69M 10-Q · filed 2023-08-03 | $11.83M 10-Q · filed 2023-08-03 | $16.74M derived: sum of 3 quarters · filed 2024-02-22 | $22.69M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2022-03-31 | $6.13M 10-Q · filed 2023-05-04 | $11.05M derived: sum of 2 quarters · filed 2024-02-22 | $17.00M derived: sum of 3 quarters · filed 2024-02-22 | $23.51M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2021-12-31 | $4.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $10.86M derived: sum of 2 quarters · filed 2024-02-22 | $17.38M derived: sum of 3 quarters · filed 2024-02-22 | $24.25M 10-K · filed 2024-02-22 | |
| 2021-09-30 | $5.95M 10-Q · filed 2022-11-03 | $12.46M derived: sum of 2 quarters · filed 2022-11-03 | $19.34M 10-Q · filed 2022-11-03 | $25.55M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-06-30 | $6.52M 10-Q · filed 2022-08-04 | $13.39M 10-Q · filed 2022-08-04 | $19.61M derived: sum of 3 quarters · filed 2023-02-23 | $24.77M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-03-31 | $6.88M 10-Q · filed 2022-05-10 | $13.09M derived: sum of 2 quarters · filed 2023-02-23 | $18.25M derived: sum of 3 quarters · filed 2023-02-23 | $23.84M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2020-12-31 | $6.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $11.38M derived: sum of 2 quarters · filed 2023-02-23 | $16.96M derived: sum of 3 quarters · filed 2023-02-23 | $21.91M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $5.17M 10-Q · filed 2021-11-04 | $10.75M derived: sum of 2 quarters · filed 2021-11-04 | $15.70M 10-Q · filed 2021-11-04 | $19.67M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-06-30 | $5.58M 10-Q · filed 2021-08-05 | $10.54M 10-Q · filed 2021-08-05 | $14.50M derived: sum of 3 quarters · filed 2022-02-24 | $18.64M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-03-31 | $4.95M 10-Q · filed 2021-05-06 | $8.92M derived: sum of 2 quarters · filed 2022-02-24 | $13.05M derived: sum of 3 quarters · filed 2022-02-24 | $17.22M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2019-12-31 | $3.97M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $8.10M derived: sum of 2 quarters · filed 2022-02-24 | $12.27M derived: sum of 3 quarters · filed 2022-02-24 | $16.53M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $4.14M 10-Q · filed 2020-11-05 | $8.30M derived: sum of 2 quarters · filed 2020-11-05 | $12.56M 10-Q · filed 2020-11-05 | $16.16M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | $4.16M 10-Q · filed 2020-08-05 | $8.43M 10-Q · filed 2020-08-05 | $12.02M derived: sum of 3 quarters · filed 2021-02-25 | $15.95M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-03-31 | $4.26M 10-Q · filed 2020-05-07 | $7.86M derived: sum of 2 quarters · filed 2021-02-25 | $11.79M derived: sum of 3 quarters · filed 2021-02-25 | $15.31M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2018-12-31 | $3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $7.52M derived: sum of 2 quarters · filed 2021-02-25 | $11.05M derived: sum of 3 quarters · filed 2021-02-25 | $13.78M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $3.93M 10-Q · filed 2019-11-06 | $7.45M derived: sum of 2 quarters · filed 2019-11-06 | $10.18M 10-Q · filed 2019-11-06 | $12.26M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-06-30 | $3.53M 10-Q · filed 2019-08-07 | $6.25M 10-Q · filed 2019-08-07 | $8.33M derived: sum of 3 quarters · filed 2020-02-27 | $10.43M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-03-31 | $2.73M 10-Q · filed 2019-05-08 | $4.81M derived: sum of 2 quarters · filed 2020-02-27 | $6.91M derived: sum of 3 quarters · filed 2020-02-27 | $8.85M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2017-12-31 | $2.08M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $4.18M derived: sum of 2 quarters · filed 2020-02-27 | $6.12M derived: sum of 3 quarters · filed 2020-02-27 | $7.95M 10-K · filed 2020-02-27 | |
| 2017-09-30 | $2.10M 10-Q · filed 2018-11-08 | $4.05M derived: sum of 2 quarters · filed 2018-11-08 | $5.87M 10-Q · filed 2018-11-08 | $7.52M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-06-30 | $1.95M 10-Q · filed 2018-08-08 | $3.77M 10-Q · filed 2018-08-08 | $5.42M derived: sum of 3 quarters · filed 2019-02-27 | $7.06M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-03-31 | $1.82M 10-Q · filed 2018-05-09 | $3.47M derived: sum of 2 quarters · filed 2019-02-27 | $5.11M derived: sum of 3 quarters · filed 2019-02-27 | $6.51M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2016-12-31 | $1.65M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $3.29M derived: sum of 2 quarters · filed 2019-02-27 | $4.69M derived: sum of 3 quarters · filed 2019-02-27 | $5.79M 10-K · filed 2019-02-27 | |
| 2016-09-30 | $1.64M 10-Q · filed 2017-11-08 | $3.04M derived: sum of 2 quarters · filed 2017-11-08 | $4.14M 10-Q · filed 2017-11-08 | $5.13M derived: sum of 4 quarters · filed 2018-03-07 | |
| 2016-06-30 | $1.40M 10-Q · filed 2017-08-09 | $2.50M 10-Q · filed 2017-08-09 | $3.49M derived: sum of 3 quarters · filed 2018-03-07 | $3.99M derived: sum of 4 quarters · filed 2018-03-07 | |
| 2016-03-31 | $1.10M 10-Q · filed 2017-05-10 | $193.00K 10-Q · filed 2016-05-11 | $2.09M derived: sum of 2 quarters · filed 2018-03-07 | $2.60M derived: sum of 3 quarters · filed 2018-03-07 | $3.20M derived: sum of 4 quarters · filed 2018-03-07 |
| 2015-12-31 | $992.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $1.50M derived: sum of 2 quarters · filed 2018-03-07 | $2.10M derived: sum of 3 quarters · filed 2018-03-07 | $2.21M 10-K · filed 2018-03-07 | |
| 2015-09-30 | $503.00K 10-Q · filed 2016-11-10 | $1.10M derived: sum of 2 quarters · filed 2016-11-10 | $1.22M 10-Q · filed 2016-11-10 | ||
| 2015-06-30 | $601.00K 10-Q · filed 2016-08-11 | $714.00K 10-Q · filed 2016-08-11 | |||
| 2014-12-31 | $22.00K 10-K · filed 2017-03-10 | ||||
| 2013-12-31 | $62.00K 10-K · filed 2016-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |